

## Our Business

GeoVax Labs, Inc. is a clinical stage biotechnology company focused on developing and commercializing human vaccines for HIV/AIDS and other infectious agents. GeoVax's unique AIDS vaccine technology is designed for use in uninfected people to protect them from AIDS should they be exposed to the virus. GeoVax's vaccine is currently entering Phase 2a trials through the US Government sponsored HIV Vaccines Trials Network (HVTN). The vaccines also may prove effective as a treatment to reduce the need for drugs in people already infected with HIV.

## Investment Highlights

- **Collaboration with Leading Institutions:** GeoVax's technology is exclusively licensed from Emory University and is the result of collaborative research conducted at Emory, the National Institutes of Health (NIH), and the Centers for Disease Control (CDC).
- **Governmental Support – Resources:** GeoVax's human clinical trials are conducted by the HIV Vaccine Trials Network (HVTN), funded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
- **Governmental Support – Funding:** GeoVax is the recipient of a 5 year, \$15 million grant awarded in October 2007 by the NIH in support of the Company's AIDS vaccine development efforts.
- **Intellectual Property:** Strong intellectual property position with 19 issued or pending patents.
- **Market:** Target disease indications represent large, global markets with an unmet medical need.

## GeoVax HIV/AIDS Vaccine

- **Practicality:** Designed to be practical and easily taken forward as a worldwide vaccine.
- **Primary Target:** Vaccinate uninfected humans in order to prevent development of AIDS.
- **Secondary Target:** Vaccinate HIV-infected humans to reduce need for drugs.
- **Properties:** DNA and MVA vaccines express the 3 major HIV proteins to stimulate anti-AIDS virus antibodies and T cells (white blood cells) in vaccinated humans.
- **Applications:** Potential to provide dual protection against HIV and smallpox.

## Intellectual Property

- 10 Filed Patents on various components and compositions of AIDS vaccine.
- 5 Patents controlling AIDS vaccine manufacturing processes.
- 4 Patents licensed from the NIH related to MVA vector vaccine as a vehicle to deliver HIV virus antigens and induce immune response in humans.

## Scientific Leadership

Dr. Harriet Robinson, Senior VP for R & D, is a pioneer in DNA vaccines and a leading researcher in HIV/AIDS vaccines. A co-founder of GeoVax, she previously served as Chief of Microbiology and Immunology for the Yerkes National Primate Research Center of Emory University.

## Management Team

**Robert T. McNally, Ph.D.**  
*President and CEO*

**Mark W. Reynolds, CPA**  
*CFO*

**Harriet L. Robinson, Ph.D.**  
*Senior V.P., Research & Development*

**Andrew J. Kandalepas**  
*Senior V.P., Investor Relations*

## Board of Directors

*Chairman*

**Donald G. Hildebrand**

*Members*

**Andrew J. Kandalepas**

**Dean G. Kollintzas**

**Robert T. McNally, Ph.D.**

**Harriet L. Robinson, Ph.D.**

**John N. Spencer**

**Peter M. Tsolinas**

## Key Information

**Stock Symbol:** GOVX (OTCBB)

**52 Week Range:** \$0.09 - \$0.29

**Market Cap (Jan09):** \$75 mil

**Website:** www.geovax.com

**IR Contact:** Financial Relations Board  
(312) 640-6667

## Vaccine Technology


GeoVax's unique two component vaccine combines DNA priming with live vector boosting (MVA) to elicit high levels of cytolytic T cells (a type of white blood cell) and blocking antibodies. Both the DNA prime and MVA boost express the three major proteins of the AIDS virus and produce non-infectious HIV-like particles. This multi-protein approach optimizes protection and limits escape by eliciting a broad multi-target cytolytic T cell response and protective binding antibody to the natural form of the HIV envelope but cannot cause AIDS.

The vaccine is the result of a multiyear collaboration between researchers at the Emory Vaccine Center, the US National Institutes of Health (NIH), and the US Centers for Disease Control and Prevention (CDC). This collaboration is developing AIDS vaccines comprising the major HIV-1 strains (AG, B and C) with primary focus on subtype B which is most common in North America, the European Community, Japan, and Australia. For worldwide use, the intent is to use the AG, B and C vaccines alone or as combinations depending on the local infection.

## Highlights: Preventative Use

After promising data were obtained in pre clinical prevention trials conducted at Emory's Yerkes Primate Center between 1998 and 2002, GeoVax's vaccine technology began human testing in Phase 1 clinical trials funded and managed by the NIH sponsored HIV Vaccine Trials Network (HVTN). On the basis of the safety and immune response data in these trials, the vaccine is currently in Phase 2a trials through the HVTN. During the past 20 years the HVTN has sponsored over 80 Phase 1 trials for the initial evaluation of safety and immunogenicity of HIV/AIDS vaccines. GeoVax's vaccine is only the fifth of these vaccines to merit moving to an HVTN Phase 2 trial.


## Preventative Use: Trial Timeline



## Highlights: Treatment Use

Recently, highly promising data obtained at the Yerkes National Primate Center demonstrated prototypes of the GeoVax vaccine ability to control infections in already infected non-human primates. In these vaccine trials, primates were infected, placed on drugs, vaccinated and then taken off drugs to determine the ability of the vaccine to control the infection. On the basis of encouraging results, human trials testing the ability of the GeoVax vaccine to act as a therapy are being planned in both adults and adolescents. These trials will involve recently infected individuals who are stably controlling their virus on antiretroviral therapy. Planning also has started to extend treatment studies to maternal to infant transmissions.

## Treatment Use: Trial Timeline



## HIV / AIDS Facts

Statistics directly impacting future market for GeoVax AIDS vaccine

- ▶ **2.5 Million** Children with HIV/AIDS in 2007
- ▶ **2.1 Million** AIDS Deaths in 2007
- ▶ **2.5 Million** Total New Infections in 2007
- ▶ **30.8 Million** Adults Living with HIV/AIDS in 2007
- ▶ **6.8 Thousand** New HIV Infections Daily in 2007
- ▶ **68.0 Million** Estimated Dead from HIV/AIDS by 2020